Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Did our DD, gold traces and huge potential copper mine. Directors in at around this price.
Should see a spike soon. Recommended this to smaller investors.
GLA, should see 15p short term.
£543k cash as of 31st March 2020, potential raising of funds soon, hopefully not via placing.
GLA all holders
For long term holders, when production proceeds and gold is extracted, this will definitely be over 10p. Will see gold and copper prices even higher than today, especially with the recession and the forecasted high inflation from the fed pumping trillions into the economy. Junior mining companies will be the investments to be and those early in will reap the rewards.
Should see many investors piling in with these figures. The marketcap should be around 40m to 50m based on figures to date, with what Kefi have underground, and calculating conservative figures over a 10 year period (including their expenses). We should see a share price of 2.8p to 5p in the near term (Between July and Sept 2020).
GLA
Look back at Kefi’s 2017 news and prices,
Things aligning together after these three years. Lots of good news ahead and a rerate back above 3p this year.
GLA to all holders.
1.395 409,702 15:05
1.4 200,000 12:02
1.4 1,750 12:02
1.44 1,500,000 12:02
1.45 300,000 WINS 14:13
1.45 300,000 SCAP 14:37
1.46 500,000 12:02
1.48 500,000 12:02
1.5 200,000 CFEP 12:02
1.5 300,000 PEEL 12:02
1.5 500,000 12:02
1.5 300,000 STFL 12:11
1.505 200,000 SING 12:02
1.65 90,000 12:02
2.05 186,172 12:02
They've applied for government funding so hopefully that comes through.
Listen from 7.47minutes in, that's where we're a bit cautious.
Happy to hold a small percentage of our portfolio here.
Just finished listening to Duncan Peyton. Lets hope a potential future fund raise is not through a placing to fund their next stage!
https://www.youtube.com/watch?v=mlL2d0-j2qI
Depth 5
07:39 CFEP 250,000 0.105
07:52 DAVY 200,000 0.1
07:54 PEEL 200,000 0.1
07:40 WINS 200,000 0.1
07:40 SCAP 250,000 0.09
5 Depth
0.11 250,000 SCAP 07:40
0.12 200,000 DAVY 07:52
0.12 200,000 PEEL 07:54
0.12 200,000 WINS 07:40
0.125 250,000 CFEP 07:39
GWMO
The demand for testing is substantial, and there is limited tests that work. Countries' are struggling to provide tests for their doctors, let alone everyday civilians. Remember Genedrive's test will immediately be bought by different governments and institutions, countries are losing billions from being shutdown and testing with tracking is required to open economies back up (unless a vaccine is found which is over 10 months away).
Genedrive's 6 million tests will no doubt be sold right away and they will continue to ramp up their testing. We foresee they will use the funds from these sales to obtain further manufacturing partners like Novacyt did, in order to ramp up production. At this moment, Genedrive are producing similar amounts of tests to Novacyt.
As the company stated, they anticipate selling their tests this month at an estimation of £8 to £10 each. You must do your own research and compare with current competitors, for example, Novacyt managed to make over £90m in sales/contracts and are continuing to expand.
All this is our opinion and we are holding and topping up.
GLA and stay safe.
FDA is required for products sold in US markets, CE marking is required for European markets. You do not need FDA and CE marking to sell in European markets, only CE.
The company will be selling in Europe this month, while awaiting for FDA approval for emergency use (which is much quicker) in order to sell to the US markets.
That's why we keep topping up and these prices.
The RNS makes things clear to us.
The test only requires a patient's sample. You can view the test on Genedrive's twitter.
Contracts will be currently negotiated right now, and we believe news stating this will be provided to the market, though Genedrive will state subject to CE marking (which will be achieved around mid May).
Should see lots of buys today and tomorrow, especially with a bank holiday Friday. The UK will be updating the country on lockdown measures on Sunday, which no doubt will inform the public again that testing and tracking must be done, along with gradually opening up the economy.
GLA and stay safe.
Waiting for the big news soon.
GLA and stay safe.
Testing will be around until a vaccine is found, which is still 10 to 14 months away at a minimum. Based on tests being sold between £8 and £10, along with Genedrive’s other commercial products and the second test priced at £20, we believe the company is severely undervalued and is now being noticed by large investors. Should see more large buys today and leading up until mid May. At this moment, we believe the current marketcap should be around £150m and £180m. We should see a rerate above 300p very soon.
Obtaining CE Mark and FDA for their Covid 19 test:
Remember, Genedrive have already got CE marked and FDA approved products, and Cytiva are a billion-dollar company with experience who have obtained CE marked and FDA approval products in the past. We are confident Genedrive will obtain the same for their tests.
Genedrive will obtain CE marking (to sell in Europe, if no one knows this) this month and begin sales this month in Europe. While Genedrive are selling their CE marked tests within the European markets, they will be waiting for FDA approval through emergency use authorisation (which has a quicker acceptance time) and therefore will then be able to sell their tests in US markets.
Regarding the funding:
The main covid 19 test players such as Avacta and Novacyt, also obtained funding, look at where they are now, and look at the impact (none) the funding had on their share price.
Genedrive’s closest comparison right now would be Avacta Group, who had funding last month at 18p, which was much lower than their share price at the time. That's just how it goes. Avacta’s share price had no effect on the placing because their future is bright, and funds were required for expansion (just like Genedrive).
It’s a shame that some sold due to panic yesterday, to then buy back at a higher price, but see this as a positive lesson learnt (and at least you’re still in still). Try not to be tricked again in the future by MMs or other investors trying to take your shares at a lower price, especially when these investment opportunities do not often come by. Always invest what you are comfortable with and not silly amounts, and always diversify.
Good luck all and stay safe.
Read the whole RNS, you already have a figure between £8 and £10 per tests, and the numbers of tests to be produced each day. The company openly mentioned those who are selling similar tests such as Novacyct, whom were struggling to meet test demands.
Genedrive will be selling their tests this month and updating investors accordingly. Do your own research and don't be panicked into selling, because you'll be kicking yourself soon. This is a great opportunity and we'll be topping up more.
Big money coming in from Bitcoin this afternoon, just watch the trades in the afternoon.
GLA and stay safe.
This will still reach over 300p again today or tomorrow, look at the charts, from where we are now, there's 0 support until 317p.
This drop happens all the time when companies are about to increase largely in marketcap, MMs shake weak investors and steal their shares. So sad to see this happen to investors.
Look at Avacta Group during their placing announcement at the beginning of April 2020, and look at where they are now?
GLA and stay safe.
Remember, Avacta did the same placing at around £50m marketcap. Look where they are now.
Funding is always required for small companies to turn into medium sized ones, Genedrive will have a marketcap of over £200m in the near future.
GLA and stay safe.
There’s barely any resistance between this price and 317p, we could see 300p today or tomorrow. Just hope our friend can sell their Bitcoins in time this afternoon, in order to get into here before 300p is reached.
Based on yesterday’s news, we now believe this could reach over 585p in the very short term.
CE certification for covid 19 test:
To note, Genedrive have a track record in receiving CE certification on their products, examples include their hepatitis-c diagnostic tests, HCV ID kit, their baby deafness diagnostic tests etc. We are very confident they will obtain CE certification with their first covid 19 test. The involvement of Cytiva gives additional reassurances.
Second covid 19 test:
With Genedrive’s long term contracts with the US Department of Defence, it wouldn’t surprise us if the company issue new US contracts involving their second covid test (which will run on the Genedrive instrument platform).
We foresee Genedrive reaching Avacta's marketcap very soon!
Investor’s do your own further research to understand the potential here. But most importantly always diversify and invest wisely.
GLA and stay safe.
We wonder how long this price will last, until investors realise how undervalued this is.
News will arrive soon. Price should be between 40p and 60p when FDA approves the ventilators. When ventilators are sold in H2, marketcap could be around £60m. These ventilators will be highly demanded.
GLA and stay safe.
Confident FDA will be achieved soon. Hopefully news by Thursday or early next week.
Should see a rerate to 20s again.
GLA!